Unclaimed Scholar Profile
Are you Robert S. Wallis? This profile has been curated from verified academic registries. Claim your profile to edit affiliations, manage works, and access your dashboard.
Verified ScholarVerified at University of the WitwatersrandASIDASID-9505-0754-1127 orcid.org/0000-0001-6152-5183
Robert S. Wallis
University of the Witwatersrand•South Africa
Faculty researcher at University of the Witwatersrand (ZA), specializing in Social Sciences & Humanities. [Discipline: Social Sciences & Humanities] [Scholar Type: Journal Research Scientist] [Career Tier: Distinguished Scholar] [Region: Southern Africa]
#Tuberculosis Research and Epidemiology#Infectious Diseases and Tuberculosis#Immune responses and vaccinations#Mycobacterium research and diagnosis
Scholarly Profiles: Google Scholar
Citation Indices
Standard Scientometrics| All | Since 2021 | |
|---|---|---|
| Citations | 14,073 | 6,755 |
| h-index | 64 | 48 |
| i10-index | 144 | 101 |
Annual Citation Growth
Verified Citations / Year0
2020676
2021+40%946
2022+29%1.2k
2023+33%1.6k
2024-8%1.5k
2025-45%811
2026Scholarship Distribution & Proportions221 Articles • 0 Books & Monographs • 0 Applied Assignments
Continental Provenance:82% African Regional Citations (11,540) • 18% Global Research Impact (2,533)
221 Indexed WorksAuthentic Data
Co-Authors & Academic Collaborators
No verified co-authors registered on AfriJournal Index yet.
Browse African Scholars →Scientific Bibliography Ingestion Notice
AfriJournal Index synchronizes authentic African citations and scholarship from Crossref, OpenAlex, and verified institutional repositories. Due to external indexing latency, some historical works may not yet be ingested in this snapshot. If you are this scholar, claim this profile to link your ORCID and verify your complete bibliography.
Articles & Books (221)
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Published in Clinical Infectious Diseases•2004
DOI: 10.1086/383317 Verified Peer-Reviewed
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
Published in European Respiratory Journal•2010
DOI: 10.1183/09031936.00028510 Verified Peer-Reviewed
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
Published in The Lancet•2010
DOI: 10.1016/s0140-6736(10)60359-5 Verified Peer-Reviewed
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
Published in The Lancet Infectious Diseases•2016
DOI: 10.1016/s1473-3099(16)00078-5 Verified Peer-Reviewed
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Published in The Lancet Infectious Diseases•2016
DOI: 10.1016/s1473-3099(16)30274-2 Verified Peer-Reviewed
Showing 1 – 5 of 221 publications
1 / 45